Type 1 Diabetes Mellitus Clinical Trial
Official title:
The Effectiveness of Glucose, Sucrose and Fructose in Treating Hypoglycemia in Children With Type 1 Diabetes
The purpose of this study is to determine the most effective treatment option for managing
naturally occurring hypoglycemia in children with type 1 diabetes.
Hypotheses:
1. Sucrose and Fructose are equally effective as glucose in the treatment of spontaneous
hypoglycemia in children with type 1 diabetes.
2. Children and teens will use a variety of treatment practices for the management of
hypoglycemia.
3. Children and teens will prefer the mode of treatment that was most effective in
treating hypoglycemia.
An open labeled, randomized, cross-over design will be used. Each subject will treat 5
hypoglycemic events with glucose, 5 with sucrose and 5 with fructose. Subjects will be
randomized into order of treatment.
Primary Objective:
1. To determine if sucrose and fructose are equally effective as glucose in the treatment
of spontaneous hypoglycemia in children with type 1 diabetes.
Secondary Objectives:
2. To determine present hypoglycemia treatment practices of children and teens with type 1
diabetes (prior to entry into the study).
3. To determine preferred mode of treatment for hypoglycemia after completing the study.
Inclusion Criteria:
The sample will consist of 65 individuals with a history of type 1 diabetes (based on
clinical presentation) for three or more months and who are between the ages of 3 and 18
years. All eligible participants will be patients of the Alberta Children's Hospital
Diabetes Clinic.
Exclusion Criteria:
Individuals with the following conditions/circumstances will be excluded from the study:
- adrenal insufficiency
- uncompensated hypothyroidism
- clinical autonomic neuropathy
- celiac disease
- lack of family support
- unwilling or unable to follow the study protocol
- subjects with less than 4 hypoglycemic events per month
Instruments:
Blood glucose will be measured with a blood glucose meter. All meters will have a lab to
meter comparison performed. In accordance with the 1998 Clinical Practice Guidelines for
Diabetes Management in Canada, an acceptable meter value will be +15% of the lab value (7).
Participants will be provided with a complimentary meter and strips.
All participants will be provided with a digital timer to enable accurate 15 minute timing
of post treatment blood glucose.
A Demographic and Pre-Study Data tool has been developed to collect pre-study information
(see Appendix B) as well as a Low Blood Glucose Treatment Log to record pre- and
post-treatment blood glucose results (see Appendix C).
Study Procedure:
A letter inviting participation in the study will be mailed to all eligible participants
(see Appendix D). Further recruitment will be done during clinic appointments. Six months
will be allocated for recruitment of subjects. Subjects will meet with the study research
assistant and informed and signed consent will be obtained. Participants will be assigned a
study number based on their order of recruitment. The research assistant and participant
will not determine treatment order. Each participant will be assigned a treatment order
based on a randomization table (See Table 1).
The research assistant will also obtain demographic data and information on present
hypoglycemia treatment practices, explain the study protocol, and provide Study Protocol
instructions (see Appendix E). The lab/meter comparison will be obtained prior to data
collection.
The study protocol is as follows:
- Hypoglycemia will be confirmed with a blood glucose test.
- If blood glucose is less than 4.0 mmol/L it will be treated with pre-packaged
treatments and in the order determined by randomization.
- The blood glucose will be re-tested 15 minutes after treatment.
- If the blood glucose is still less than 4.0 mmol/L, it will be treated again as per
study protocol and then re-tested 15 minutes later.
- If the next meal or snack is more than 1 hour away, a snack containing 15 g of
carbohydrate and a protein will be eaten.
- Participants will record blood glucose results and treatment method on the Low Blood
Glucose Treatment Log.
If participants can not follow the above outlined protocol, they will be instructed to treat
as per usual practice and not record data. This will mean that most hypoglycemic events
treated as per protocol will likely occur when children are with their parents or in the
comfort of their own homes.
Assuming that children and teens will experience 1 to 3 hypoglycemic events per week, it is
anticipated that data collection will occur over a 5 to 15 week period. The research
assistant will call participants every two weeks to monitor study progress. Once the subject
has treated 15 hypoglycemic episodes as per study protocol and completed the Low Blood
Glucose Treatment Log, they will return it in a pre-addressed and stamped envelope. There
will be a question at the end of the Low Blood Glucose Treatment Log asking preferred method
of hypoglycemia treatment following completion of the study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A |